Universität zu Köln

Prince, H. Miles, Hutchings, Martin ORCID: 0000-0003-3873-1741, Domingo-Domenech, Eva, Eichenauer, Dennis A. and Advani, Ranjana ORCID: 0000-0002-3219-2292 (2023). Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Ann. Hematol., 102 (1). S. 13 - 30. NEW YORK: SPRINGER. ISSN 1432-0584

Full text not available from this repository.

Abstract

CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL), and some cutaneous T-cell lymphomas. The antibody-drug conjugate brentuximab vedotin targets CD30-positive cells and has been evaluated for the treatment of various lymphoma entities. This narrative review summarizes 10 years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses novel therapies targeting CD30 in development, and highlights remaining controversies relating to CD30-targeted therapy across lymphoma types. The collective body of evidence for brentuximab vedotin demonstrates that exploitation of CD30 can provide sustained benefits across a range of different CD30-positive lymphomas, in both clinical trials and real-world settings. Preliminary experience with brentuximab vedotin in combination with immune checkpoint inhibitors for relapsed/refractory cHL is encouraging, but further exploration is required. The optimal use of brentuximab vedotin for first-line therapy of PTCL remains to be determined. Further research is required on brentuximab vedotin treatment in high-risk patient populations, and in rare lymphoma subtypes, for which no standard of care exists. Novel therapies targeting CD30 include chimeric antigen receptor therapies and bispecific antibody T-cell engagers, which may be expected to further improve outcomes for patients with CD30-positive lymphomas in the coming years.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Prince, H. Miles UNSPECIFIED UNSPECIFIED UNSPECIFIED Hutchings, Martin UNSPECIFIED orcid.org/0000-0003-3873-1741 UNSPECIFIED Domingo-Domenech, Eva UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichenauer, Dennis A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Advani, Ranjana UNSPECIFIED orcid.org/0000-0002-3219-2292 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-688546
DOI:	10.1007/s00277-022-05054-9
Journal or Publication Title:	Ann. Hematol.
Volume:	102
Number:	1
Page Range:	S. 13 - 30
Date:	2023
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-0584
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PERIPHERAL T-CELL; REFRACTORY HODGKIN LYMPHOMA; BRENTUXIMAB-VEDOTIN; CD30 EXPRESSION; OPEN-LABEL; MYCOSIS-FUNGOIDES; PHYSICIANS CHOICE; SINGLE-CENTER; STAGE-III; PHASE-III Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68854